Identification of KIF20A as a Tumor Biomarker and Promoter of Clear Cell Renal Cell Carcinoma
Renal cell carcinoma (RCC) is one of the top 10 most common cancers in adults, with clear cell renal cell carcinoma (ccRCC) being the most prevalent and aggressive subtype. Despite advances in treatment, ccRCC remains associated with high mortality rates due to local recurrence and distant metastasis after nephrectomy. Tyrosine kinase inhibitors (TKIs) have shown promise in treating advanced ccRCC, but resistance to these therapies often develops, leading to poor patient outcomes. Therefore, there is an urgent need to identify novel prognostic biomarkers and therapeutic targets for ccRCC.
Kinesin family member 20A (KIF20A) and KIF20B have been implicated as oncogenes in various cancers. In this study, the expression profiles of KIF20A and KIF20B were analyzed in ccRCC tissues using data from The Cancer Genome Atlas Kidney Clear Cell Carcinoma (TCGA-KIRC) database. The results revealed that both KIF20A and KIF20B were significantly upregulated in ccRCC tissues compared to normal renal tissues. Specifically, KIF20A expression was elevated in 533 ccRCC tissues and 72 paired ccRCC and normal tissues. Kaplan-Meier survival analysis demonstrated that patients with high KIF20A expression had significantly shorter overall survival (OS) and disease-free survival (DFS) compared to those with low KIF20A expression. In contrast, KIF20B expression did not show a significant correlation with patient survival.
Univariate and multivariate analyses further confirmed that KIF20A is an independent risk factor for ccRCC. The hazard ratios (HR) for OS and DFS were 1.741 and 1.470, respectively, indicating that high KIF20A expression is associated with worse patient outcomes. Receiver operating characteristic (ROC) curve analysis demonstrated that KIF20A has high diagnostic efficiency for distinguishing ccRCC tissues from normal tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) results also confirmed the upregulation of KIF20A in ccRCC tissues, suggesting its potential as a diagnostic biomarker.
To explore the biological role of KIF20A in ccRCC, the researchers constructed short hairpin RNA (shRNA) plasmids targeting KIF20A (sh-KIF20A-1 and sh-KIF20A-2) and transfected them into 786-O and A498 renal cancer cell lines. The successful knockdown of KIF20A was confirmed at both the mRNA and protein levels. Gene set enrichment analysis (GSEA) revealed that KIF20A is involved in the G2/M checkpoint and epithelial-mesenchymal transition (EMT) signaling pathways, both of which are critical for cancer progression. Silencing KIF20A significantly inhibited the proliferation, migration, and invasion of 786-O and A498 cells, as demonstrated by cell counting kit-8 (CCK-8) assays and migration/invasion assays. These findings suggest that KIF20A plays a crucial role in promoting the malignant characteristics of ccRCC cells.
The study also highlighted the potential of KIF20A as a therapeutic target for ccRCC. The suppression of KIF20A expression not only inhibited cancer cell proliferation and migration but also disrupted key signaling pathways involved in tumor progression. These results align with previous reports that identified KIF20A as a significant player in cancer biology, although its specific role in ccRCC had not been fully elucidated prior to this study.
In conclusion, this study identified KIF20A as a novel prognostic biomarker and potential therapeutic target for ccRCC. The upregulation of KIF20A in ccRCC tissues was associated with poor patient outcomes, and its knockdown inhibited the malignant behavior of renal cancer cells. These findings underscore the importance of KIF20A in ccRCC pathogenesis and suggest that targeting KIF20A could be a promising strategy for improving patient prognosis. However, further research involving larger patient cohorts is needed to validate the clinical utility of KIF20A as a biomarker and therapeutic target.
DOI: 10.1097/CM9.0000000000001331
Was this helpful?
0 / 0